Toyota|$17.85 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.21 (¥4,312)-1.21%▼ (in JPY terms)
SoftBank|$19.09 (¥3,025)-14.48%▼ (in JPY terms)
MUFG|$19.09 (¥3,024)-5.41%▼ (in JPY terms)
Keyence|$88.52 (¥14,025)-4.53%▼ (in JPY terms)
Nintendo|$55.74 (¥8,832)-5.09%▼ (in JPY terms)
NTT|$1.06 (¥168)-0.71%▼ (in JPY terms)
Takeda|$44.01 (¥6,973)+0.33%▲ (in JPY terms)
Tokyo Electron|$52.44 (¥8,309)-7.06%▼ (in JPY terms)
Recruit|$106.25 (¥16,835)-5.50%▼ (in JPY terms)
ITOCHU|$14.19 (¥2,248)-1.88%▼ (in JPY terms)
Honda|$10.96 (¥1,737)-2.99%▼ (in JPY terms)
Shin-Etsu|$33.05 (¥5,237)-5.28%▼ (in JPY terms)
Tokio Marine|$3.64 (¥578)+2.03%▲ (in JPY terms)
Fast Retailing|$518.91 (¥82,220)-1.38%▼ (in JPY terms)
Toyota|$17.85 (¥2,828)+1.25%▲ (in JPY terms)
Sony|$27.21 (¥4,312)-1.21%▼ (in JPY terms)
SoftBank|$19.09 (¥3,025)-14.48%▼ (in JPY terms)
MUFG|$19.09 (¥3,024)-5.41%▼ (in JPY terms)
Keyence|$88.52 (¥14,025)-4.53%▼ (in JPY terms)
Nintendo|$55.74 (¥8,832)-5.09%▼ (in JPY terms)
NTT|$1.06 (¥168)-0.71%▼ (in JPY terms)
Takeda|$44.01 (¥6,973)+0.33%▲ (in JPY terms)
Tokyo Electron|$52.44 (¥8,309)-7.06%▼ (in JPY terms)
Recruit|$106.25 (¥16,835)-5.50%▼ (in JPY terms)
ITOCHU|$14.19 (¥2,248)-1.88%▼ (in JPY terms)
Honda|$10.96 (¥1,737)-2.99%▼ (in JPY terms)
Shin-Etsu|$33.05 (¥5,237)-5.28%▼ (in JPY terms)
Tokio Marine|$3.64 (¥578)+2.03%▲ (in JPY terms)
Fast Retailing|$518.91 (¥82,220)-1.38%▼ (in JPY terms)

2026-11-20 Eisai Co.,Ltd. “The results of a cerebrospinal fluid substudy analysis on alpha-synuclein-associated pathology from the recanemab Clarity AD trial were presented at CTAD 2026. Recanemab showed favorable results on clinical assessment scales at 18 months of administration, even in patients with early Alzheimer's disease who were alpha-synuclein-positive and associated with greater amyloid accumulation and faster clinical progression.”

2026-11-20 Eisai Co.,Ltd. “The results of a cerebrospinal fluid substudy analysis on alpha-synuclein-associated pathology from the recanemab Clarity AD trial were presented at CTAD 2026. Recanemab showed favorable results on clinical assessment scales at 18 months of administration, even in patients with early Alzheimer's disease who were alpha-synuclein-positive and associated with greater amyloid accumulation and faster clinical progression.”

コメントする